Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Vistagen logo — Changing the trajectory of mental health care – One Mind at...

Vistagen

Changing the trajectory of mental health care – One Mind at a Time

Founded 1998 United States South San Francisco, United States 58 employees Post-IPO Equity Total: $154.75M Biotechnology, Pharmaceutical

General Information

Company Name Vistagen
Founded Year 1998
Location United States South San Francisco, United States
Founders / Decision Makers
Team member
Employees 58
Industries Biotechnology, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Vistagen. To contact Vistagen, visit vistagen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Vistagen compare?

A PDF of Vistagen and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Vistagen soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Vistagen

Vistagen is a late clinical-stage biopharmaceutical company, traded on Nasdaq under the ticker symbol VTGN, that is revolutionizing mental health care with its pioneering neuroscience approach. The company's focus is on developing first-in-class therapies for psychiatric and neurological disorders. Vistagen has six clinical-stage product candidates, five of which belong to a new class of drugs known as pherines - fasedienol (PH94B), itruvone (PH10), PH80, PH15, and PH284. These investigational neuroactive nasal sprays have innovative proposed mechanisms of action, activating chemosensory neurons in the nasal passages to impact neural circuits in the brain without systemic absorption or receptor binding. Additionally, Vistagen’s sixth clinical-stage product candidate, AV-101, is an investigational oral drug candidate with the potential to inhibit NMDA receptor activity. Founded in 1998, Vistagen operates in the biotechnology and pharmaceutical industries, with its headquarters in the United States. The company recently secured a significant investment of $100.00M in post-IPO equity from a consortium of notable investors including BVF Partners, Commodore Capital, Logos Capital, Nantahala Capital, TCG Crossover, Great Point Partners, and Surveyor Capital on 02 October 2023. With its focus on transforming the treatment of anxiety, depression, and other neuroscience disorders, Vistagen stands at the forefront of innovative, potentially game-changing therapies for mental health.

Business keywords: biopharmaceutical company, neuroscience, clinical-stage product candidates, psychiatric disorders, neurological disorders, pherines, neuroactive nasal sprays, NMDA receptor activity, AV-101, central nervous system, MDD, drug development, mental health, innovation, therapy

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $100.00M 7
BVF Partners Commodore Capital Logos Capital
BVF Partners, Commodore Capital +5
02 Oct 2023
Post IPO Equity $10.00M -
02 Jun 2016
Post IPO Equity $1.93M -
06 Aug 2015
Post IPO Equity $1.57M -
02 Jul 2014
Post IPO Equity $36.00M -
10 Apr 2013
Post IPO Debt $500.00K -
07 Mar 2012
Venture Round $1.00M 1
California Institute for Regenerative Medicine
22 Dec 2008
Venture Round $3.75M 1
Montaur Capital Partners
10 Aug 2007

Vistagen Alternatives & Competitors

View All Alternatives
Vistagen vs
Relmada Therapeutics, Inc
Relmada Therapeutics, Inc United States

Relmada (Nasdaq: $RLMD) is a clinical-stage company developing novel therapies for the treatment of...

Post-IPO Equity
32 employees
Biotechnology, Pharmaceutical
Compare Vistagen vs Relmada Therapeutics, Inc
Vistagen vs
Longboard Pharmaceuticals
Longboard Pharmaceuticals United States

We Are Committed To Transforming the Lives of Patients With Neurological and Rare Diseases.

Post-IPO Equity
81 employees
Biotechnology, Health Care
Compare Vistagen vs Longboard Pharmaceuticals
Vistagen vs
Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. United States

The era of genetic neuroscience has arrived

IPO
244 employees
Biotechnology, Health Care
Compare Vistagen vs Praxis Precision Medicines, Inc.
View all alternatives

FAQ About Vistagen

Changing the trajectory of mental health care – One Mind at a Time
Vistagen was founded in 1998.
Vistagen is headquartered in South San Francisco, United States.
Vistagen operates in Biotechnology and Pharmaceutical. Its work centres on biopharmaceutical company, neuroscience, clinical-stage product candidates and psychiatric disorders.
Vistagen has approximately 58 employees.
Vistagen has completed 8 funding rounds, raising a total of $154.75M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Vistagen include Relmada Therapeutics, Inc, Longboard Pharmaceuticals, Praxis Precision Medicines, Inc., Seelos Therapeutics, Inc., Euthymics Bioscience. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Vistagen and Relmada Therapeutics, Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Vistagen, https://bouncewatch.com/company/vistagen-1, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout